ストックスクリーナーアプリを入手
0.8123
0.78%
0.0063
アフターアワーズ：
.85
0.0377
+4.64%
前日終値:
$0.806
開ける：
$0.81
24時間の取引高:
27,100
Relative Volume:
0.12
時価総額：
$62.80M
収益：
$8.23M
当期純損益:
$-32.49M
株価収益率:
-1.5326
EPS:
-0.53
ネットキャッシュフロー:
$-19.91M
1週間 パフォーマンス:
+0.16%
1か月 パフォーマンス:
+10.52%
6か月 パフォーマンス:
-16.26%
1年 パフォーマンス:
-36.04%
1日の値動き範囲:
$0.81
$0.83
1週間の範囲:
$0.77
$0.83
52週間の値動き範囲:
$0.7001
$1.65
Clearside Biomedical Inc Stock (CLSD) Company Profile
名前
Clearside Biomedical Inc
セクター
電話
678-270-3631
住所
900 NORTH POINT PARKWAY, ALPHARETTA, GA
CLSD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLSD
Clearside Biomedical Inc
|
0.8123 | 62.80M | 8.23M | -32.49M | -19.91M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-21 | 開始されました | Chardan Capital Markets | Buy |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2021-12-15 | 再開されました | Wedbush | Outperform |
| 2021-07-29 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-13 | 開始されました | ROTH Capital | Buy |
| 2019-08-09 | ダウングレード | Needham | Buy → Hold |
| 2018-11-05 | ダウングレード | Cowen | Outperform → Market Perform |
| 2018-11-05 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2018-11-05 | ダウングレード | Stifel | Buy → Hold |
| 2018-03-06 | 繰り返されました | Needham | Buy |
| 2017-05-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2017-02-24 | 開始されました | JP Morgan | Overweight |
| 2016-11-10 | 繰り返されました | Needham | Buy |
| 2016-10-24 | 繰り返されました | Stifel | Buy |
すべてを表示
Clearside Biomedical Inc (CLSD) 最新ニュース
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting - GlobeNewswire
Clearside Biomedical Announces Multiple Presentations to be Feat - GuruFocus
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting | CLSD Stock News - GuruFocus
Clearside Biomedical Showcases Suprachoroidal Injection Platform for Retinal Diseases at CTS Meeting - Nasdaq
Comprehensive Age-related Macular Degeneration Market Analysis: Trends and Developments Across All Types - GlobeNewswire Inc.
Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Northern Trust Corp Has $157,000 Holdings in Clearside Biomedical, Inc. (NASDAQ:CLSD) - Defense World
Clearside Biomedical Approves Share Increase at Annual Meeting - TipRanks
Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know - MSN
Clearside Biomedical (CLSD) Gets a Buy from H.C. Wainwright - The Globe and Mail
Clearside Biomedical’s SWOT analysis: eye disease stock faces funding hurdles amid promising pipeline - Investing.com India
Clearside Biomedical target cut to $5 by H.C. Wainwright - Investing.com
HC Wainwright Lowers Clearside Biomedical (NASDAQ:CLSD) Price Target to $5.00 - Defense World
Clearside Biomedical (CLSD) Price Target Lowered by Analyst | CL - GuruFocus
H.C. Wainwright Adjusts Price Target for Clearside Biomedical (C - GuruFocus
Clearside Biomedical (CLSD) Price Target Lowered by Analyst | CLSD Stock News - GuruFocus
Clearside Biomedical to Participate in a Fireside Chat at the St - GuruFocus
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum | CLSD Stock News - GuruFocus
Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum - GlobeNewswire
Clearside Biomedical Reveals Next-Gen Eye Therapy Platform at Exclusive Stifel Conference - Stock Titan
Analysts Set Clearside Biomedical, Inc. (NASDAQ:CLSD) Price Target at $5.00 - Defense World
JMP Securities Reiterates “Market Outperform” Rating for Clearside Biomedical (NASDAQ:CLSD) - Defense World
Clearside Biomedical (NASDAQ:CLSD) Raised to Hold at StockNews.com - Defense World
Needham & Company LLC Lowers Clearside Biomedical (NASDAQ:CLSD) Price Target to $3.00 - Defense World
JMP maintains $5 target on Clearside Biomedical stock By Investing.com - Investing.com Nigeria
Clearside Biomedical (CLSD) Reiterates Market Outperform Rating - GuruFocus
Clearside Biomedical Reports Q1 2025 Financial Progress - TipRanks
Clearside Biomedical (CLSD) Target Price Lowered by Needham | CL - GuruFocus
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates - MSN
Stifel maintains Buy on Clearside Biomedical, target at $8 By Investing.com - Investing.com South Africa
Stifel maintains Buy on Clearside Biomedical, target at $8 - Investing.com Australia
Clearside Biomedical Inc (CLSD) Q1 2025 Earnings: EPS Matches Es - GuruFocus
Clearside (CLSD) Reports Strong Q1 Revenue Boost | CLSD Stock Ne - GuruFocus
Clearside Biomedical Inc (CLSD) Q1 2025 Earnings: EPS Matches Estimates at -$0.11, Revenue Surges to $2.3 Million, Exceeding Expectations - GuruFocus
Clearside Biomedical Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CLEARSIDE BIOMEDICAL Earnings Results: $CLSD Reports Quarterly Earnings - Nasdaq
Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Clearside (CLSD) Reports Strong Q1 Revenue Boost | CLSD Stock News - GuruFocus
Clearside's Wet AMD Drug Advances to Phase 3: FDA Green Light Could Transform Eye Disease Treatment - Stock Titan
Clearside Biomedical Inc (CLSD) Q1 2025 Earnings Report Preview: What To Expect - GuruFocus
Clearside Biomedical (NASDAQ:CLSD) Cut to “Sell” at StockNews.com - Defense World
Investor Network: Clearside Biomedical, Inc. to Host Earnings Call - ACCESS Newswire
Clearside Biomedical Inc (CLSD) 財務データ
収益
当期純利益
現金流量
EPS
Clearside Biomedical Inc (CLSD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Chong Ngai Hang Victor | Chief Medical Officer |
Nov 01 '24 |
Buy |
1.00 |
36,500 |
36,500 |
100,000 |
0.68%
0.50%
大文字化:
|
ボリューム (24 時間):